Maple Grove, MN – August 2, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) announced the launch of Bexarotene Capsules, 75 mg (the branded product: Targretin®* ). The product was approved by the U.S. Food and Drug Administration (FDA) on July 25. It has added another product to its growing generic portfolio, supporting the Company’s commitment to expanding and diversifying its product offerings. The company has launched three new products this fiscal year.
Bexarotene Capsules 75 mg is prescribed for the treatment of cutaneous manifestations of cutaneous T cell lymphoma (CTCL).
* Targretin is a registered trademark of Valeant Pharmaceuticals International, Inc, or its affiliates.
About Upsher-Smith
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, we’ve brought specialty generics and other products to a wide array of customers, backed by our attentive level of service, our strong industry relationships, and our dedication to uninterrupted supply. As we approach our 100th year in business, we enter a new ambitious era that has been accelerated by our 2017 acquisition by Sawai Pharmaceutical Co., Ltd. With our new owner, we look to leverage each other for growth worldwide and embark on an exciting new chapter. Together, we seek to deliver the best value for our stakeholders, and most importantly, do more good for the patients we serve. For more information, visit https://www.upsher-smith.com.